1. What every physician needs to know:

Chronic obstructive pulmonary disease (COPD) refers to all lung diseases characterized by a decrease in expiratory airflow that is not completely reversible.

The term is usually employed in describing increased resistance to airflow in the small airways caused by excessive inflammation following chronic exposure to noxious inhaled substances. In contrast, asthma, although also a disease characterized by chronic obstruction to airflow, entails reversible airway inflammation that occurs in response to environmental antigens.

In COPD, the obstruction is expiratory in nature since airway resistance is greatest during the end of expiration, when the small airway lumen has the smallest diameter and offers the greatest resistance. This issue is important with regard to both symptoms and management outcome.

Although COPD exists in those who have never smoked and does occur in patients under age forty-five, the overwhelming majority of cases arise in the fifth and sixth decades of life and are related to chronic cigarette smoke exposure. Dust exposure results in a similar risk of developing COPD to that of exposure to biomass fuel smoke or cigarette smoke.

Although rare, genetic causes, specifically, alpha-1 anti-trypsin (A1AT) deficiency,should be ruled out in newly diagnosed COPD, as specific intervention may be offered for this disorder.

_{Reposted with permission from Decision Support in Medicine, LLC.}

2. Classification:

Chronic bronchitis is defined as cough or sputum production for at least three months per year for two or more years. Sputum production, which predominantly reflects inflammation of the medium and large airways, tends to be directly related to the irritating effects of ongoing smoke or dust exposure. Many studies suggest that smokers with chronic bronchitis and normal lung function are more likely to progress to COPD than are those without chronic bronchitis. Smoking cessation may result in resolution of chronic bronchitis and reduction in the risk of progression to COPD. Compared to COPD patients without chronic bronchitis, patients with chronic bronchitis have a greater risk of exacerbations and disease progression and tend to be current smokers.

Emphysema is defined as permanent enlargement of alveolar spaces because of the destruction of alveolar walls. The pathologic changes are irreversible and are due to proteolytic destruction of the matrix framework of the alveoli. The loss of alveoli structure reduces lung elastic recoil, decreases the ability of the lung to tether open the small airways, and obliterates the pulmonary microcirculation involved in gas exchange. Patients with the emphysematous form of COPD generally have more dyspnea and weight loss and a greater risk for development of lung cancer than do COPD patients without emphysema.

Smoking-induced bronchiolitis is defined as inflammation of the small airways associated with smoke exposure. Smoke-induced bronchiolitis spans a spectrum from modest changes in small airway function to respiratory bronchiolitis-interstitial lung disease (RB-ILD). The small airways appear to be the first site of inflammation in young, otherwise healthy smokers; they also appear to be the initial area of airway remodeling in COPD. Functional loss of small airways probably occurs prior to development of emphysema.

Alpha-1 anti-trypsin (A1AT)-deficient emphysema is due to deficiency of the most abundant serum protease inhibitor (A1AT), resulting in significant increased risk for both smoke- and occupation-induced COPD. A1AT deficiency commonly occurs at a younger age (the fourth or fifth decades) than typical COPD and results in a more homogeneous pattern of emphysema. A1AT deficiency may present with symptoms of asthma (in the absence of atopy) or bronchiectasis, even when emphysema is not severe. A1AT deficiency is easily excluded by testing serum A1AT levels.

Although each of these entities may be considered separate and distinct, they usually occur together, with one or more predominating in affected individuals.

^{Reposted with permission from Decision Support in Medicine, LLC.}

3. Are you sure your patient has COPD? What should you expect to find?

The most common clinical manifestations of COPD, as discussed in detail elsewhere include:

Exertional dyspnea
Cough
Sputum production
Wheeze
Chest tightness/chest pain
Anorexia/weight loss
Spontaneous pneumothorax
Unexpected hypoxemia

_{Reposted with permission from Decision Support in Medicine, LLC.}

4. Beware: there are other diseases that can mimic COPD:

The differential diagnosis of COPD is broad, and it includes many considerations, among them:

Asthma
Heart failure
Coronary artery disease
Bronchiectasis
Atypical pneumonia
Tuberculosis
Physical deconditioning
Restrictive lung diseases (including sarcoidosis and idiopathic pulmonary fibrosis)
Chronic fungal or atypical mycobacterial lung infections
Bronchiolitis

_{Reposted with permission from Decision Support in Medicine, LLC.}

5. How and/or why did the patient develop COPD?

In developed countries, the predominant risk factor for development of COPD is cigarette smoking. According to the National Health and Nutrition Examination Survey (NHANES), dust and fumes may also cause COPD. After smoking and other confounders are accounted for, a slightly increased incidence of COPD is seen in certain occupations, including construction, plastics manufacturing, and utility work.

Only about 5 percent of physician-diagnosed COPD occurs in non-smokers. COPD in non-smokers is more common in those with asthma and in older individuals.

A key question in the pathogenesis of COPD is why so many people with significant exposure to known causes are spared the disease. Studies clearly show an increase in macrophage-predominant inflammation in the alveolar spaces and terminal bronchioles of current smokers. However, only 20 percent or fewer of chronic smokers develop symptomatic COPD. The current theory is that environmental, developmental, and genetic risk factors combine to create susceptibility to enhanced lung inflammation and failure of defenses against lung destruction (Figure 1).

Normal lung function is maximal at eighteen to twenty years of age. Maximal lung function may be significantly decreased by environmental or genetic factors in some asymptomatic individuals. The normal, age-related decline in lung function may be accelerated by environmental toxins like cigarette smoke. Although smoking cessation alters the rate of decline, some former smokers and many older individuals will eventually experience a decline in lung function below that which defines obstructive lung disease. However, the risk of respiratory specific mortality remains low until significant loss of lung function occurs.

Variations in lung development, age-related decline in lung function, and exposure to noxious substances result in variable, age-dependent development of COPD. The nonmeasurability of genetic and environmental effects, along with an ability to estimate tobacco smoke exposure only roughly results in poor accuracy in predicting development of COPD in chronic smokers.

Individual differences in molecular pathogenic mechanisms of smoking-induced lung remodeling likely result in the variation of emphysematous versus airway predominant disease phenotype despite the same inciting cause.

Which individuals are at greatest risk of developing COPD?

Risk factors can be classified as environmental and genetic. The relative contribution of each in patients with COPD cannot be defined. Ideally, future studies will permit a directed therapeutic approach, based upon risk for disease progression.

_{Reposted with permission from Decision Support in Medicine, LLC.}

6. Environmental risk factors for the development of COPD

Although cigarette smoke exposure is the predominant risk factor for development of COPD, occupational exposure to heavy dust or fumes or exposure to smoke from incomplete combustion of biomass fuels like wood smoke are likely to be equally as dangerous. Significant research interest focuses on the relationship between airway hyper-reactivity and development of COPD. Hyper-reactivity appears to occur after obstructive lung disease arises. Whether adolescent asthma and antigen exposure predispose to COPD in adults is unclear.

Chronic cough and sputum production may predict a subset of smokers with increased risk for developing COPD. Whether the quantity of environmental exposure relates to sputum production or cough is unknown; in patients with established COPD, cough and sputum production are more common in current smokers. The role of early-life lung infections as an environmental risk for development COPD has been debated. Although there are models of injury during lung development that lead to alveolar hypoplasia, a direct relationship between risk of COPD and common childhood lung infections is not established.

Longitudinal studies suggest that early smoking by females may have a greater effect on maximal lung development than it does with males, and the effect may continue for a few years longer than it does in men, placing adolescent women at a much lower starting point for lung function before smoking-related declines occur. Whether females are at greater risk of early COPD because of a more rapid decline in function or because of the effects of smoking on lung development is unclear. Multiple studies have suggested a greater prevalence of severe COPD in women. Although women have historically had lower exposures to tobacco smoke and environmental fumes than men have, this may change as more adolescent women decide to smoke.

Alpha-one antitrypsin deficiency as a genetic risk for COPD development

The most significant genetic risk factor for development of COPD is deficiency in A1AT (Serpin A1). Although the enzyme inhibits trypsin, its ability to inhibit neutrophil elastase is key to preventing development of lung disease. Neutrophils entering the lungs of patients with A1AT deficiency cause more lung destruction than they do in those without the deficiency because of unopposed enzyme activity in areas of the lung with low inhibitor levels (Figure 2).

Wide, unexplained variations in disease severity in individuals with comparable levels of A1AT deficiency, even after adjusting for smoking history, demonstrate the daunting task of establishing causality of other genetic polymorphisms of lesser pathogenic impact in the production of lung disease. The frequency of lung function testing in individuals with early-onset emphysema or atypical asthma who are tested for A1AT deficiency is nearly as low as the frequency of lung function testing in symptomatic smokers. Subjects suspected of having A1AT deficiency can be easily screened with a simple blood test available at most institutions. There is little reason for limiting screening of appropriate patients for this uncommon--but not rare--genetic disorder.

Differences in the levels of circulating A1AT protein (phenotype) are observed among individuals with the less severe S allele and those with the more severe Z allele. Individuals who have an SZ genotype and an SZ phenotype are at a lower risk for development of COPD than are those with the ZZ phenotype. Whether individuals heterozygous for A1AT deficiency (MZ genotype) are at increased risk of accelerated emphysema is a subject of much debate.

Although concern about disease is less in MZ heterozygotes, in the absence of environmental risk, accumulating data suggest smokers who have as much as 50 percent of the normal circulating protein (MZ "carriers") are at increased risk. Given that smoking is uncommon in individuals who know they have severe A1AT deficiency (ZZ and SZ phenotypes), the low absolute risk of having MZ or SS genotypes should not limit efforts to caution individuals with lower risk genotypes and to discuss the familial risk of smoking with their children and siblings.

Genetic predispositions other than A1AT deficiency for COPD development

Two basic approaches have been utilized to search for other genetic risk factors in subjects with COPD: the candidate gene approach and genome-wide association studies (GWAS):

The candidate gene approach, in which a gene suspected of a disease relationship (based on biologic plausibility) is investigated in a fair-sized cohort, is the more common approach. Important information may be uncovered using this technique, as significant positive findings may be observed even in fairly small cohorts. Unfortunately, failure to confirm positive findings often leads to more speculation regarding the roles of ethnicity, phenotypes, and other factors specific to the population studied. Given the data on phenotypic presentation in A1AT deficiency, this speculation is not surprising.

GWAS have been performed with widespread collections of biologic samples for genetic testing from large cohorts of patients with COPD. This approach, which is not hypothesis-driven, offers unique and often unexpected results. Like the candidate gene approach, GWAS may lead to erroneous conclusions, despite study of large populations. The technique is based on locations of gene polymorphisms, where there are large areas of linkage disequilibrium; therefore, while results may identify a region with a gene that can be potentially implicated in disease pathogenesis, the region may contain other genes related to lung development or smoking behavior.

For example, the leading candidate genes for development of both lung cancer and COPD are members of a gene family of nicotinic acetylcholine receptor alpha chains (CHRNA). However, given the potential for members of this gene family to interact with smoking behavior, causation and risk may be only indirectly related.

Other findings from GWAS suggest that we have overlooked the effect of abnormal lung development on subsequent risk for COPD (and asthma). Some genes discovered as genetic modifiers of COPD risk are also important in determining the heritability of lung function in individuals without disease. An example is the hedgehog interacting protein (HHIP), which is part of a pathway involved in limb patterning and embryonic development. An area near the HHIP gene is associated with both lung disease and a reduction in lung function in individuals with no overt disease. These findings reflect the complexity of the genetic risk for COPD, environmental influences, and our historical use of arbitrary measures (e.g., a fixed ratio of FEV₁ to FVC) in defining the presence of disease (Figure 3).

With all of these caveats noted, genetic associations suggest that gene variations that influence antioxidants, protease/antiprotease balance, lung development, and cigarette smoking are important contributors to development of COPD. However, none of these suspected genetic modifiers has yet reached a level of clinical applicability to warrant patient screening or counseling to reduce the risk of COPD.

_{Reposted with permission from Decision Support in Medicine, LLC.}

7. What laboratory studies should you order to help make the diagnosis, and how should you interpret the results?

No blood test is diagnostic of COPD or useful in excluding it. Similarly, no blood or sputum test is helpful in tailoring or adjusting existing therapy. Studies that look for possible candidates as biomarkers of disease progression are listed in the bibliography. Currently, clinical judgment supersedes existing available laboratory studies in establishing the diagnosis.

If obstructive lung disease is present in the clinical setting of bronchiectasis, immunoglobulin levels, aspergillus serology, A1AT levels, and possibly sweat chloride or rheumatoid factor testing may be indicated as ruling out entities other than cigarette smoking as the predominant cause of obstruction and bronchiectasis. Sputum for non-tuberculous mycobacteria (NTM) may be useful in patients with bronchiectasis and a productive cough; if clinical suspicion of NTM is high, direct sampling with bronchoscopy may be necessary to exclude the diagnosis.

Symptoms of right heart failure in mild or moderate COPD might suggest concomitant obstructive sleep apnea (overlap syndrome). Right heart failure occurring in more severe COPD may represent pulmonary hypertension. A resting room air arterial blood gas can be performed, and if an elevated PaCO2 is present, symptom-guided additional studies are warranted. Given the high prevalence of cardiovascular disease in patients with COPD, symptoms of right heart failure may also be due to left heart failure. A normal PaCO2 in this setting may suggest need for further cardiac work-up. Resting hypoxemia and hypercarbia are independent prognostic factors suggestive of shorter survival in COPD.

The presence of hypoxemia in the setting of severe obstructive lung disease is unpredictable, and the need for supplemental oxygen in severe obstructive lung disease should be considered at baseline as well as when any significant change in clinical status occurs.

What imaging studies will be helpful in making or excluding the diagnosis of COPD?

Many infectious causes of symptoms similar to those in COPD can be evaluated with a simple chest radiograph (e.g., to rule-out active tuberculosis). However, so-called "classic" radiographic findings of COPD, including increased anterior-posterior diameter and flattened diaphragms, are not specific to the disorder. Many of these changes are seen with normal aging.

Although a CT scan may be useful in ruling out the presence of other lung diseases, the clinical relevance of a radiologic description of mild emphysema on CT is unclear since age-appropriate normals are not available. A chest CT scan reading of emphysema should trigger pulmonary function testing rather than establishment of a diagnosis.

If interstitial lung disease or bronchiectasis is clinically suspected, a thin-section, high-resolution chest CT scan is indicated. Mild bronchiectasis may be seen in both A1AT deficiency and smoking-related COPD. However, moderate or severe bronchiectasis warrants additional evaluation for infectious and non-infectious causes other than COPD.

Since most subjects who undergo evaluation for COPD have an increased risk for lung cancer, based on current available data, a "low dose" cancer screening CT scan may be justified. The National Lung Screening Trial (NLST) demonstrated a survival benefit of annual lung CT scans in a population of subjects who were forty-five years of age or older, had a thirty-pack-year or greater smoking history, and who were within five years of quitting smoking or were still actively smoking.

Although small inflammatory nodules are commonly noted on CT scans performed in smokers and in those living in areas where histoplasmosis is endemic, the NLST included sufficient numbers of subjects in these categories to justify the additional, potentially invasive procedures that will be generated by false-positive scans.

_{Reposted with permission from Decision Support in Medicine, LLC.}

8. What non-invasive pulmonary diagnostic studies will be helpful in making or excluding the diagnosis of COPD?

The diagnosis of COPD is based on pulmonary function testing. All smokers with dyspnea or symptoms of chronic bronchitis should undergo pre- and post-brochodilator pulmonary function testing. A reduction in expired airflow is the sina qua non for the diagnosis of COPD. Hence, pulmonary function testing is the cornerstone of establishing the diagnosis and is fundamental in assessing its severity and in predicting mortality. The spirometric standard for COPD is a persistent or permanent reduction of FEV₁/FVC below a fixed ratio of 0.7. A growing consensus is that, since patients with severe airflow obstruction may be unable to achieve complete exhalation during a forced expiratory maneuver, measurement of FEV₆(forced expiratory volume at six seconds) may be an adequate surrogate for FEV₁/FVC.

Severity of COPD is determined by the magnitude of the reduction in FEV₁ compared with normative values based on height, gender, race, and age. Since aging results in a disproportionate decrease of FEV₁relative to FVC, spirometrically defined COPD becomes prevalent in healthy non-smokers who live long enough. Accordingly, some have suggested using the lower limit of normal (LLN) for FEV₁/FVC, defining values that comprise the lowest 5 percent of the population as abnormal.

However, this approach does not appear to improve markedly the diagnosis of COPD in otherwise asymptomatic individuals. In fact, evaluation of a population-based cohort indicated that prediction of the rate of subsequent hospitalization for respiratory reasons was higher using the fixed-ratio method than it was using the LLN-based approach. (Presumably, the latter approach is more reflective of indolent disease in asymptomatic individuals.) In addition, post-bronchodilator measurements are preferred in defining obstruction in order to prevent misclassification of reversible disease. Many older, population-based studies did not assess post-bronchodilator measures.

Current guidelines from the Global Initiative on Obstructive Lung Disease (GOLD), which use the fixed-ratio method (FEV₁/FVC <0.7) to define airway obstruction, stress the use of post-bronchodilator measurements. Although, in order to avoid overlap with asthma, studies of COPD commonly exclude patients with significant reversibility, those with significant airflow obstruction despite partial reversibility have COPD. In fact, patients with fixed expiratory airflow obstruction commonly demonstrate some reversibility that varies between physician visits. Furthermore, a significant response to methacholine following development of fixed airflow obstruction in COPD is common despite absence of a history of childhood asthma. However, a positive methacholine challenge test or documentation of reversible airflow obstruction does not reliably predict who among asymptomatic smokers will develop COPD with continued smoking.

Since pulmonary fibrosis is more prevalent in smokers, combined pulmonary fibrosis and emphysema (CPFE) may sometimes be present with attendant "pseudo-normalization" of spirometry and lung volumes. For this reason, further work-up of a low DLCO noted in the absence of clear obstructive lung disease may be an indication of the need for a high-resolution chest CT scan.

Once the diagnosis of COPD has been established, patients with severe disease (GOLD Stage IV, FEV₁< 30% predicted; see below) may benefit from a test for exercise-associated desaturation or a six-minute walk test. The BODE index, a tool that incorporates measurements of body mass index (B), airflow obstruction (O), dyspnea (D), and exercise capacity (E), utilizes the six-minute walk distance, in conjunction with other common measurements (FEV₁, body mass index, and Medical Research Council Dyspnea Score), to predict survival in COPD.

_{Reposted with permission from Decision Support in Medicine, LLC.}

9. What diagnostic procedures will be helpful in making or excluding the diagnosis of COPD?

Depending on symptoms, additional cardiac or cardiopulmonary exercise testing may be indicated, particularly if spirometry suggests an alternative diagnosis.

What pathology/cytology/genetic studies will be helpful in making or excluding the diagnosis of COPD?

The diagnosis of COPD is not based on cytologic or genetic studies.

If you decide the patient has COPD, how should the patient be managed?

_{Reposted with permission from Decision Support in Medicine, LLC.}

10. Medical Management

Severity in COPD is defined by the degree of expiratory airflow obstruction, expressed as FEV1 as a percent of predicted value. The GOLD stages are defined as Stage I (FEV₁% > 80% predicted), Stage II (FEV₁% < 80% but > 50% predicted), Stage III (FEV_1,% < 50% but >30% predicted), and Stage IV (FEV₁%, <30% predicted). Management is based on the stage of disease (Figure 4) (Figure 5).

For Stage I disease, smoking cessation is the main goal. If smoking cessation is successful at this stage, progression to more severe disease may be prevented and cardiovascular and cancer risks reduced.

For Stage II disease, smoking cessation and symptomatic therapies are both considered (Figure 3). Symptomatic therapies include both short- and long-acting beta-agonists (LABA) and long-acting anti-muscarinics (LAMA). Although most therapies approved for Stage II disease offer no survival benefit, recent data suggest that, in some patients, some therapies may decrease the frequency of exacerbations and may provide a survival benefit. The longest-acting agents may provide the greatest benefit. Therapeutic decisions in Stage II and Stage III disease can be considered with regard to those that improve symptoms alone, those that prevent exacerbations, and those that may be shown to improve survival.

Stage IV disease is commonly accompanied by hypoxemia. Treatment of significant hypoxemia (PaO₂< 55 mm Hg) with supplemental oxygen provides a survival benefit that is greater for those treated continuously throughout the day than for those treated only nocturnally. Compelling evidence is lacking for use of supplemental oxygen for less severe hypoxemia, even in patients who have severe airflow obstruction and dyspnea. Only patients with significant hypoxemia have improvement in exercise capacity with use of supplemental oxygen.

Chronic nocturnal ventilation may be utilized for symptomatic hypercarbia and may result in clinical improvement; however, its use may not improve the patient's ability to perform activities of daily living, nor may it confer a survival benefit. Pulmonary rehabilitation can be utilized for any disease stage; however, since health insurance benefits are commonly limited, rehabilitation therapy is usually prescribed only for those with severe disease and limited abilities to perform activities of daily living.

_{Reposted with permission from Decision Support in Medicine, LLC.}

11. Surgical Management

For selected patients and those with severe disease, surgical options may be considered, including lung volume reduction surgery (LVRS) and lung transplantation. Many patients with COPD are not candidates for either procedure for a variety of reasons, including significant comorbidities. However, when utilized appropriately, these approaches may improve quality of life and chances of survival. Smoking cessation is an absolute requirement before consideration of any surgical options.

The mechanism for clinical improvement with LVRS is thought to be related to enhanced lung elastic recoil. Surgical removal of lung areas that have lost elastic recoil reduces hyperinflation in the remaining lung and restores ventilation to preserved parts of the lung that were previously compressed. Safe and successful application of LVRS requires appropriate patient selection: Those with heterogeneous, upper lobe-predominant disease, and a low exercise capacity after completing pulmonary rehabilitation (defined as <gender specific 40th percentile maximum workload - 25W in women, 40W in men) derive the greatest benefit, while individuals with an FEV₁ less than 20 percent predicted with either DLCO greater than 20 percent predicted or homogeneous emphysema have increased mortality and no benefit.

Since institution- and surgeon-specific volume are important determinants of outcomes, patients are likely to travel to referral institutions for surgery. Therefore, knowledge of these factors and evaluation of cardiac and other factors related to the ability to tolerate surgery can optimize referral practice. A1AT deficiency-related emphysema does not benefit from surgery. Although subjects with upper-lobe-predominant disease and a high exercise capacity do not gain a mortality benefit, there is sufficient improvement in measures of quality of life to warrant individualized discussions of risk and benefit, given the relatively long survival in otherwise healthy individuals with severe emphysema.

In a retrospective analysis of a subset of patients evaluated with automated software, six-month improvement in FEV1, exercise capacity, and respiratory-specific quality of life had a weak but significant correlation with pre-operative ratios of upper lobe versus lower lobe disease severity. Although increased mucus plugs in the resected tissue have been correlated with survival, CT analysis of airway wall thickness offer no predictive information on outcomes.

Lung transplantation provides a less clear survival advantage in COPD, when survival on the waiting list was compared with post-transplant survival. In the United States, organ allocation has been adjusted to reflect this fact. However, lung transplantation clearly enhances quality of life in patients with severe COPD who are good surgical candidates.

_{Reposted with permission from Decision Support in Medicine, LLC.}

12. Symptom-Based Therapy

In addition to the critically important issue concerning whether a patient with COPD continues to smoke is that concerning whether he or she experiences frequent acute exacerbations. Frequent exacerbations are generally considered to be three or more exacerbations over the preceding three years. In addition to the incremental morbidity and cost, data suggest that lung function decline is also steeper with frequent exacerbations.

Use of inhaled corticosteroids (ICS) may be benefit patients with frequent exacerbations; otherwise, the incremental risk of pneumonia associated with use of ICS, although small, may outweigh their benefit.

Phosphodiesterase-4 (PDE4) inhibitors also appear to benefit patients with chronic bronchitis who experience frequent exacerbations of bronchitis. However, unlike use of ICS, PDE4 inhibitors are suggested only for those with GOLD Stage III or Stage IV disease. Whether there is additional benefit from adding a PDE4 inhibitor to a regimen of ICS and a long-acting beta agonist is unknown.

Both ICS and PDE4 inhibitors benefit current smokers and former smokers; hence, smoking does not preclude benefit from anti-inflammatory therapies. Caution should be used in prescribing the PDE4 inhibitor, Roflumilast, as insomnia, anxiety, and significant weight loss may occur with its use. In GOLD Stages III and IV, depression and low body mass index may limit the pool of candidates appropriate for this therapy.

Macrolides may be useful in reducing the frequency of acute exacerbations, but their use may also increase development of drug-resistant mycobacteria.

_{Reposted with permission from Decision Support in Medicine, LLC.}

13. Use of Beta Adrenergic Blocking Agents

Because cardiovascular morbidity and mortality are common in COPD, a practical question regarding management concerns whether to tailor therapy for the lung disease to accommodate cardiac concerns, or vice versa. Beta-adrenergic blocking agents provide a survival benefit in coronary artery disease so their use should not be limited to COPD. Furthermore, although use of short-acting bronchodilators as rescue agents may be called into question in the setting of active coronary artery disease, large trials that incorporate the use of long-acting beta agonists and include patients with coronary atherosclerosis provide a clear safety profile and indicate a trend toward survival benefit.

_{Reposted with permission from Decision Support in Medicine, LLC.}

14. What is the prognosis for patients managed in the recommended ways?

Most patients with GOLD Stages I or II disease will not die of respiratory failure but are likely to die of non-respiratory causes before ever reaching GOLD Stage IV.

Generally, survival even in severe COPD is fairly long, so significant disability and morbidity may occur before palliative care decisions are entertained. Although survival predictions can be estimated using rules based on selected parameters, such as the BODE index (discussed previously), a realistic, patient-specific prediction regarding survival is not possible. Clearly, although the presence of hypoxemia or hypercarbia offers additional prognostic information, a formulaic application that incorporates these parameters to predict survival does not exist.

The outcome in COPD may be best viewed with respect to symptomatic improvement in treated versus untreated disease. Most of the single-drug and combination therapies previously discussed provide a clinically significant improvement in quality of life. A discussion of the improvement achieved using pharmacologic agents constitutes an important aspect of patient care, as a patient's lack of perceived benefit may not only limit the use of medications but also interfere with smoking abstinence. Studies that incorporate longer time frames for evaluating the effect of medications on survival suggest a survival benefit.

_{Reposted with permission from Decision Support in Medicine, LLC.}

15. What other considerations exist for patients with COPD?

Future therapy for COPD may include adjuvants for lung regeneration.

^{Reposted with permission from Decision Support in Medicine, LLC.}

16. What’s the evidence?

Deaths from chronic obstructive pulmonary disease--United States, 2000-2005. MMWR 2008;57(45):1229-32.

Summary of statistics on COPD-related mortality, noting an increase over the five-year period encompassed.

Agusti A, Calverley PM, Celli B, et al. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research 2010;11:122.

A broad look at the demographics of a COPD referral-based population."Typical" referral-based populations may differ from patients seen in individual practices.

Anzueto A. Primary care management of chronic obstructive pulmonary disease to reduce exacerbations and their consequences. American Journal of the Medical Sciences 2010;340(4):309-18.

Review of COPD therapies and evidence-based treatment recommendations.

Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343(4):269-80.

Broad overview of COPD pathogenesis.

Bon JM, Leader JK, Weissfeld JL, et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PloS One 2009;4(8):e6865.

Assessment of the utility of a panel of serum biomarkers applied to a population of patients in a large cancer screening program. While biomarker candidates of interest can be identified, no serum test can be recommended in patient management based on these results.

Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65(8):719-25.

Evaluation of the safety of long-acting beta-agonists in a large trial that included subjects with coronary artery disease.

Castaldi PJ, Cho MH, Cohn M, et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Human Molecular Genetics 2010;19(3):526-34.

Summary of the current results of genetic approaches to uncovering important COPD risk-related genes.

Celli BR. Predictors of mortality in COPD. Respiratory Medicine 2010;104(6):773-9.

Summary of the current data and usefulness of the BODE index in predicting survival in COPD.

Celli BR, Halbert RJ. Point: should we abandon FEV/FVC <0.70 to detect airway obstruction? No. Chest 2010;138(5):1037-40.

Commentary on the debate around defining COPD using a fixed value for FEV1/FVC versus an approach based on the lower limit of normal (LLN).

Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The NETT part II: lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med 2011 [electronic version]. Retrieved from http://ajrccm.atsjournals.org/cgi/reprint/201103-0455CIv1.

Summary of the short- and long-term outcome results of the largest lung volume reduction surgery trial with important subgroup analysis that should influence referral practice.

de Torres JP, Casanova C, Pinto-Plata V, et al. Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. PloS One 2010;6(1):e16021.

Summary of the results of the use of a panel of plasma biomarkers in COPD. No clear plasma test can be recommended to determine therapeutic decisions.

DeMeo DL, Campbell EJ, Brantly ML, et al. Heritability of lung function in severe alpha-1 antitrypsin deficiency. Human Heredity 2009;67(1):38-45.

Discussion of the influence of factors other than A1AT levels on lung function in patients with severe A1AT deficiency.

Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182(5):693-718.

Discussion of the relative importance of environmental (other than cigarette-smoke related) and genetic effects on development of COPD.

Fletcher C, Peto R. The natural history of chronic airflow obstruction. British Medical Journal 1977;1(6077):1645-8.

Original longitudinal study of the relationship between smoking and decline in lung function.

Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009;361(27):2599-608.

Large trial that confirmed the utility of the candidate gene approach as a useful method in detecting genes associated with COPD severity. However, the magnitude of risk and the lack of test availability preclude its use for genetic counseling or in applications of specific therapeutics.

Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of chronic obstructive pulmonary disease: an analysis of the COPD gene study. Available at: http://chestjournal.chestpubs.org/content/early/2011/04/06/chest.10-2948.long.

Description of the characteristics associated with the chronic bronchitis phenotype in a large referral-based cohort of patients with COPD. Active smoking and frequent acute exacerbations are associated with this phenotype.

Lin K, Watkins B, Johnson T, Rodriguez JA, Barton MB. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force. Annals Internal Med 2008;148(7):535-43.

Guidelines for the use of spirometry in screening for COPD.

O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease: 2008 update: highlights for primary care. Can Respir J 2008;15 Suppl A:1A-8A.

Concise review of contemporary treatment recommendations in COPD.

Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163(5):1256-76.

Comprehensive review of COPD diagnosis and treatment.

Pickard AS, Jung E, Bartle B, Weiss KB, Lee TA. Coded cause of death and timing of COPD diagnosis. COPD 2009;6(1):41-7.

Discussion of the relationship between the duration of the COPD diagnosis and cause of death.

Silverman EK, Sandhaus RA. Clinical practice: Alpha1-antitrypsin deficiency. N Engl J Med 2009;360(26):2749-57.

Summary of the pathophysiology and clinical management of A1AT deficiency.

Sorheim IC, Bakke P, Gulsvik A, et al. Alpha-antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010;138(5):1125-32.

A look at the risk of even mild A1AT deficiency in the longitudinal loss of lung function.

Tashkin D, Celli B, Kesten S, Lystig T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respiratory Medicine 2010;104(10):1495-504.

Report of results of the long-term use of the long-acting muscarinic antagonist (LAMA) tiotropium in a large cohort of patients with COPD. Multiple outcomes, including FEV1, quality of life, frequency of exacerbations, and respiratory mortality, demonstrate benefit. Subset analyses suggest that early use of the drug in mild or moderate, symptomatic COPD is justified, even in young patients.

Telenga ED, Kerstjens HA, Postma DS, Ten Hacken NH, van den Berge M. Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. Expert Opinion on Pharmacotherapy 2010;11(3):405-21.

Summary of trials involving inhaled corticosteroids with or without concomitant use of long-acting beta-agonists in COPD.

The National Lung Screening Trial Research Team. Reduced lung cancer mortality with low-dose computed tomography screening. N Engl J Med 2011. Available at: www.nejm.org/doi/full/10.1056/NEJMoa1102873.

Summary of results of the largest lung cancer screening trial comparing chest radiography with computed tomography in a broad population of greater than thirty-pack-year smokers that resulted in a significant survival benefit. Includes evaluation of the impact of such a high rate of false-positive scans that will require invasive diagnostic procedures if this practice is adopted.

Washko GR, Martinez FJ, Hoffman EA, et al. Physiological and computed tomographic predictors of outcome from lung volume reduction surgery. Am J Respir Crit Care Med 2010;181(5):494-500.

Interesting approach using retrospective data to offer a possible prediction of non-mortality outcomes of LVRS that may influence decisions regarding surgical referral.

^{Reposted with permission from Decision Support in Medicine, LLC.}

COPD: Pathogenesis, Epidemiology, and the Role of Cigarette Smoke

3. Are you sure your patient has COPD? What should you expect to find?